Photo from wikipedia
Cannabidiol (CBD) expanded access program, initiated in 2014, provided add‐on CBD to patients with treatment‐resistant epilepsies (TREs) at 35 US epilepsy centers. Prior publications reported results through December 2016; herein,… Click to show full abstract
Cannabidiol (CBD) expanded access program, initiated in 2014, provided add‐on CBD to patients with treatment‐resistant epilepsies (TREs) at 35 US epilepsy centers. Prior publications reported results through December 2016; herein, we present efficacy and safety results through January 2019.
Keywords:
resistant epilepsies;
treatment resistant;
expanded access;
access program;
efficacy safety;
patients treatment
Journal Title: Epilepsia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Epilepsia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!